Moolec Science (MLECW) Other Non-Current Liabilities (2022 - 2026)
Moolec Science (MLECW) posted Other Non-Current Liabilities of $300000.0 for Q1 2026, up 71.12% sequentially from $175316.0 in Q4 2025.
Moolec Science (MLECW) Other Non-Current Liabilities (2022 - 2026) Analysis & Trends
Moolec Science has reported Other Non-Current Liabilities for 5 years, with the latest figure at $300000.0 in Q1 2026.
- Quarterly Other Non-Current Liabilities changed N/A year-over-year to $300000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $300000.0 (changed N/A YoY) and the FY2025 annual result came in at $16.2 million, down 7.61% from the prior year.
- Other Non-Current Liabilities advanced to $300000.0 in Q1 2026 per MLECW's latest filing, from $175316.0 in the prior quarter.
- Over five years, Other Non-Current Liabilities peaked at $17.5 million in Q2 2024 and troughed at $175316.0 in Q4 2025.
- A 5-year average of $3.6 million and a median of $1.2 million in 2023 frame the typical range for Other Non-Current Liabilities.
- The widest YoY moves for Other Non-Current Liabilities: up 937.27% in 2024, down 68.08% in 2024.
- Over 5 years, Other Non-Current Liabilities stood at $1.7 million in 2022, then declined by 28.52% to $1.2 million in 2023, then plunged by 58.48% to $494578.0 in 2024, then sank by 64.55% to $175316.0 in 2025, then soared by 71.12% to $300000.0 in 2026.
- According to Business Quant data, Other Non-Current Liabilities over the past three periods registered $300000.0, $175316.0, and $16.2 million for Q1 2026, Q4 2025, and Q2 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | Moolec Science | 8,617.72 | -1.19 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 300,000.00 |
| Dec 31, 2025 | 175,316.00 |
| Jun 30, 2025 | 16.15 Mn |
| Dec 31, 2024 | 494,578.00 |
| Sep 30, 2024 | 587,111.00 |
| Jun 30, 2024 | 17.48 Mn |
| Mar 31, 2024 | 1.25 Mn |
| Dec 31, 2023 | 1.19 Mn |
| Sep 30, 2023 | 1.84 Mn |
| Jun 30, 2023 | 1.69 Mn |
| Mar 31, 2023 | 356,757.00 |
| Dec 31, 2022 | 1.67 Mn |